Evaluation of response, tolerability and toxicity of new chemotherapeutic regimen in advanced Gastric Cancer
Abstract
Background:This study testing the effectiveness ,toxicity and tolereability of new chemotherapeutic regimen (consist of Irinotecan 5-FU and Leucovorin) in locally advanced and metastatic Gastric Cancer.
Patients and Methods: Patients with locally advanced gstric cancer (atleast stage 3)or metastatic gastric cancer that no treated previously with chemotherapeutic agents entered onto this study. Treatment consist of 6-12 cycles (every 2 weeks) with Irinotecan(CPT-11)140mg/m2iv,Lecovorin100mg/m2iv ,followed by 5-FU 400mg/m2(in4hours)and then 5-FU 1200m2(ci in 48h),all cycles given every 2 weeks and repeated atleast for 6 cycles(6-12 cycles).
Results: Ten(10) patients were enrolled and eligible patients received this protocol therapy.The over all response rate was 60% and 10% complete response,and50% with partial response and 10% stable disease. Median survival was 13 months and median event free survival was 8 months. The major toxicity was Neutropenia (grade 4) in 3 cases(30%), that two cases died in neutropenic sepsis feature.Grade 4 anemia was observed in one case that needs to transfusion therapy. Other mild side effect and toxicity of this protocol therapy were: Grade 1 neutropenia(10%),mild thrombocytopenia(10%),mild diarrhea (40% )mild nausea and vomiting (60%)and lethargia and mucositis were not seen.
Conclusion: This protocol consist of Irinotecan iv bolous that followed with Leucovorin and 5-FU in 4h and then 5-FU in 48h ci is very active in patients with locally advanced and metastatic Gastric Cancer. Diarrhea and mucositis were less than other reports. Future trials in large series need to documented effectiveness and tolereability and toxicity of this new protocol.
- Schoffski P. New drug for treatment of gastric cancer. Ann Oncol. 2002; 13 suppl 4:13-22.
- Nishikubo C, Haskell C. Chemotherapy for gastric cancer treatment. 5th ed. New York: WB Saunders Company; 2001. p. 693-696.
- Blanke CD, Haller DG, Benson AB, et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol. 2001;12(11):1575-1580.
- Köhne CH, Catane R, Klein B, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer. 2003;89(6):997-1001.
- Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14 Suppl 2:ii31-36.
- Mayer RJ. Gastrointestinal tract cancer. In: Kasper DL, Braunward E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison principle of internal medicine. 16th ed. New York, NY: McGraw‐Hill; 2005. p. 524-527.
- Buiatti E, Palli D, Decarli A, et al. A case-control study of gastric cancer and diet in Italy. Int J Cancer. 1989;44(4):611- 616.
- Phase II-III chemotherapy studies in advanced gastric cancer. The Gastrointestinal Tumor Study Group. Cancer Treat Rep. 1979;63(11-12):1871-1876.
- Comis RL, Carter SK. Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev. 1974;1(4):285-304.
- Kelsen DP, Magill GB, Cheng E, et al. Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep. 1983;67(5):509-510.
- Lacave AJ, Izarzugaza I, Antón Aparicio LM, et al. Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol. 1983;6(1):35-38.
- Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998;4(4):269-274.
- Einzig AI, Lipsitz S, Wiernik PH, Benson AB 3rd. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Invest New Drugs. 1995;13(3):223-227.
- Einzig AI, Lipsitz S, Wiernik PH, Benson AB 3rd. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Invest New Drugs. 1995;13(3):223-227.
- Klein HO. Long-term results with FAMTX (5- fluorouracil, adriamycin, methotrexate) in advanced gastric cancer. Anticancer Res. 1989;9(4):1025-1026.
- Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999;80(1- 2):269-272.
- Yokokura T, Sawada S, Nokata K, et al. Antileukemic activity of new camptothecin derivatives. Proceedings of the Japanese Cancer Association, 40th Annual Meeting, Sapporo, Japan, 1981:228a.
- Yokokura T, Furuta T, Sawada S, et al. Antitumor activity of newly synthesized, lactone ring-closed and water-soluble camptothecin derivative in mice. Proceedings of the Japanese Cancer Association, 43rd Annual Meeting, Fukuoka, Japan, 1984:261a.
- Kunimoto T, Nitta K, Kanaka T, et al. Antitumor activity of 7-ethyl-10[4-(1-piperidino)-1-piperidino]-1-carbonyloxy- camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987;47:5944–5947.
- Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho. 1994;21(7):1033-1038.
- Pozzo C, Bugat R, Peschel C, et al. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: final results of a randomised phase II study. Proc Am Soc Clin Oncol 2001;20:(Abstr 531).
- Findlay MPN, Ackland S, Gebski V, et al. Phase II study of irinotecan, leucovorin and 5- FU (ILF) in advanced gastric cancer. Proc Am Soc Clin Oncol. 2001;20:165a.
| Files | ||
| Issue | Vol 3, No 1 (2009) | |
| Section | Articles | |
| Keywords | ||
| Irinotecan Leucovorin 5fluorouracil Gastric cancer | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
